Mayo Clinic researchers identify proteins linked to immunotherapy resistance in metastatic colorectal cancer
A discovery by Mayo Clinic researchers may help explain why immunotherapy hasn't been helpful for many patients with metastatic colorectal cancer. In findings published in Clinical Cancer Research, the team identified specific proteins — fibronectin and smooth muscle actin — within colorectal cancer tissues that are associated with resistance to immunotherapy treatment.
Immunotherapy is a major advance in treating cancer, but many patients, including those with metastatic colorectal cancer, do not respond to it. Until now, researchers have not known why.
'We need predictive biomarkers to guide the selection of immunotherapy for patients,' says medical oncologist and gastroenterologist Frank Sinicrope, M.D. , the senior author of the study. 'Identifying those who may have resistance to treatment can be useful because then we can spare them from receiving treatment that may not be beneficial and could produce significant toxicities.'
The research team used digital spatial profiling, an advanced technology that simultaneously analyzes the expression of multiple proteins and where they are located within tissues. This approach allowed researchers to zoom in to get a bird's eye view of a tumor that includes proteins both within and surrounding the tumor cells and how they interact.
Dr. Sinicrope compares the spatial tools to an aerial view of a neighborhood where one can see relationships between driveways, houses, yards and neighboring structures. Similarly, this detailed view provides physicians and researchers with critical information about the proteins in and around a patient's cancer, potentially informing the best treatment for the patient.
'We wanted to learn more about the patients who did not respond to immunotherapy. We investigated the leading edge of the tumor where cancer cells are invading and where the immune system is attempting to fight the cancer,' says Dr. Sinicrope. 'It's like a battle going on here and we're getting a snapshot into who is in attendance.'
The researchers focused on 10 regions at the invasive margin of a tumor. They applied digital spatial profiling to investigate 71 distinct proteins in both the tumor's epithelial compartment and the surrounding stromal compartment. Fibronectin and smooth muscle actin are two extracellular matrix proteins that were found in the epithelial region of the tumor and were associated with resistance to immunotherapy and shorter time before disease progression.
Upon further analysis, the researchers observed that cancer-associated fibroblasts were producing these proteins. The evidence, they say, suggests that these proteins can contribute to suppression of the anti-tumor immune response.
The discovery offers a step toward more personalized and effective colorectal cancer treatments.
Review the study for a complete list of authors, disclosures and funding.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Web Release
13-05-2025
- Web Release
Mayo Clinic researchers identify proteins linked to immunotherapy resistance in metastatic colorectal cancer
A discovery by Mayo Clinic researchers may help explain why immunotherapy hasn't been helpful for many patients with metastatic colorectal cancer. In findings published in Clinical Cancer Research, the team identified specific proteins — fibronectin and smooth muscle actin — within colorectal cancer tissues that are associated with resistance to immunotherapy treatment. Immunotherapy is a major advance in treating cancer, but many patients, including those with metastatic colorectal cancer, do not respond to it. Until now, researchers have not known why. 'We need predictive biomarkers to guide the selection of immunotherapy for patients,' says medical oncologist and gastroenterologist Frank Sinicrope, M.D. , the senior author of the study. 'Identifying those who may have resistance to treatment can be useful because then we can spare them from receiving treatment that may not be beneficial and could produce significant toxicities.' The research team used digital spatial profiling, an advanced technology that simultaneously analyzes the expression of multiple proteins and where they are located within tissues. This approach allowed researchers to zoom in to get a bird's eye view of a tumor that includes proteins both within and surrounding the tumor cells and how they interact. Dr. Sinicrope compares the spatial tools to an aerial view of a neighborhood where one can see relationships between driveways, houses, yards and neighboring structures. Similarly, this detailed view provides physicians and researchers with critical information about the proteins in and around a patient's cancer, potentially informing the best treatment for the patient. 'We wanted to learn more about the patients who did not respond to immunotherapy. We investigated the leading edge of the tumor where cancer cells are invading and where the immune system is attempting to fight the cancer,' says Dr. Sinicrope. 'It's like a battle going on here and we're getting a snapshot into who is in attendance.' The researchers focused on 10 regions at the invasive margin of a tumor. They applied digital spatial profiling to investigate 71 distinct proteins in both the tumor's epithelial compartment and the surrounding stromal compartment. Fibronectin and smooth muscle actin are two extracellular matrix proteins that were found in the epithelial region of the tumor and were associated with resistance to immunotherapy and shorter time before disease progression. Upon further analysis, the researchers observed that cancer-associated fibroblasts were producing these proteins. The evidence, they say, suggests that these proteins can contribute to suppression of the anti-tumor immune response. The discovery offers a step toward more personalized and effective colorectal cancer treatments. Review the study for a complete list of authors, disclosures and funding.
Web Release
10-05-2025
- Web Release
Can diet help with inflammatory bowel disease?
Inflammatory bowel disease (IBD) is a chronic inflammation of the digestive tract. It includes conditions such as ulcerative colitis and Crohn's disease. In this expert alert, Amanda Johnson, M.D. , a gastroenterologist at Mayo Clinic, helps explain IBD and whether diet can help. People with IBD may experience persistent symptoms like frequent diarrhea, weight loss, abdominal pain and fatigue. There is no cure and no exact cause, though researchers continue to look at how genes, the microbiome and environmental factors play a role in this chronic disease. 'Ulcerative colitis really tends to only involve the colon and be more of a superficial type inflammation; whereas Crohn's disease can impact anything in the intestine, essentially, from the mouth all the way down to the anus,' says Dr. Johnson. She says diet alone does not cause IBD. While some foods may reduce symptoms, there is no one proven diet to control inflammation. 'The right diet is probably different for each individual, based on the type of IBD that they have, the location of their disease, whether they've had surgeries or other complications,' says Dr. Johnson. Focus on fresh fruits and vegetables and whole grains. Avoid ultraprocessed foods, added sugars and animal fats. And drink plenty of water to stay hydrated. Diet does not replace medical treatment. Dr. Johnson says there are effective treatment options, so it is important to work with your healthcare team. 'The tenant of therapy we have are immune-suppressing-type therapies that try to target that inappropriate response to the intestines and then calm down that inflammation within the gut,' she says.
Zawya
06-05-2025
- Zawya
Swiss Medical Network joins Mayo Clinic Care Network
Collaboration strengthens ties with GCC patients, who now represent 32% of international patient inflow UAE - Swiss Medical Network and Mayo Clinic are joining forces with seven leading institutions, - Clinique de Genolier, Privatklinik Bethanien, Clinica Sant'Anna, as well as Swiss Visio Genolier, Swiss Visio Montchoisi, Swiss Visio Zurich and Swiss Visio Ticino – are joining the Mayo Clinic Care Network. The collaboration comes at a time when Swiss Medical Network is further deepening its engagement with GCC patients, who account for 32 per cent of its international patient inflow. The partnership also aligns with the growing demand for premium, culturally attuned healthcare services in the region, reinforcing Switzerland's position as a preferred destination for specialised treatments. Swiss Medical Network is the first institution in Western Europe to join the Mayo Clinic Care Network, a select group of medical institutions worldwide that collaborate with Mayo Clinic to advance excellence in patient care. As part of the Mayo Clinic Care Network, Swiss Medical Network and Mayo Clinic will collaboratively leverage their globally recognized expertise, advanced medical knowledge, and best practices to elevate the standard of healthcare excellence in Switzerland. In collaboration with Mayo Clinic's expertise, this partnership aims to develop advanced preventive care, including executive health and check-up programs, foster ophthalmology research, and promote advanced nursing education. Cancer patients seeking a second opinion will benefit from a dedicated tumor board uniting Mayo Clinic specialists and Swiss Medical Network experts for personalized, multidisciplinary treatment. "We are pleased to welcome Swiss Medical Network to the Mayo Clinic Care Network,' said Eric J. Moore, M.D., head and neck surgical oncologist and medical director, Mayo Clinic International. 'Our collaboration is built on shared values and a commitment to patient-centered care. As we have worked together toward this day, both organizations share similar values and a commitment to providing high-quality, patient-centered care. We look forward to collaborating and innovating in ways that enhance that care. Dino Cauzza, CEO of Swiss Medical Network, emphasized the significance of this relationship, 'As a member of Mayo Clinic Care Network, this is an opportunity for Swiss Medical Network and, most importantly, for our patients. By integrating Mayo Clinic's expertise into our network, we reinforce our commitment to providing exceptional, patient-focused care. Through this partnership we will also accelerate the development of our executive health and check-up programs as a key element of preventive health in our vision of integrated care. This is a defining moment in our journey toward medical excellence.' With medical tourism projected to reach USD 142.7 billion by 2032, the demand for advanced healthcare services in complex surgeries, oncology, orthopaedics, and preventive medicine continues to rise among GCC citizens and residents. In such a scenario, Swiss Medical Network will sustain its efforts to deliver tailored healthcare solutions that match the expectations and preferences of GCC patients, ensuring seamless access to world-class expertise and patient-centred care. Swiss Medical Network and other members of the Mayo Clinic Care Network remain independent, while benefiting from a global ecosystem of medical innovation and shared knowledge. Established in 2011, the Mayo Clinic Care Network now includes over 45 leading healthcare organizations across the United States, Europe, the Middle East, Asia, India, and Mexico. About Swiss Medical Network Swiss Medical Network is one of Switzerland's two leading private hospital and clinic groups. With 21 clinics and hospitals, over 70 outpatient centers, 5,000 employees and more than 2,300 doctors practicing in 15 cantons, the group covers the entire medical spectrum, operates listed and contracted hospitals, and cares for more than 1.2 million patients a year. A pioneer in integrated care with the VIVA project, the Réseau de l'Arc has become the leading integrated care organization in Switzerland, now accessible to a large proportion of the population of the Jura Arc. At the beginning of 2025, the launch of VIVA in Ticino and Rete Sant'Anna extended this model, reinforcing the Group's commitment to integrated care accessible to all in Switzerland. Swiss Medical Network is an 77%-owned subsidiary of AEVIS VICTORIA SA, listed on the SIX Swiss Exchange. About Mayo Clinic Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.
